DDX17 and central nervous system cancer: Similarly, high DDX17 expression leads to a worsened prognosis for patients with glioma (17), gastric cancer (149), pancreatic cancer (150), colon cancer (151), paclitaxel-resistant ovarian cancer (152), and other cancers.